GSK gets the vaccine edge on Pfizer
US experts favour GSK’s RSV vaccine over Pfizer’s, but both could be on the market soon.
CROI 2023 – progress on efforts to cure HIV
Aelix and Gilead, Immunocore and Corvus are all taking different approaches in the early hunt for a functional cure.
Spybiotech seeks new vaccines
With CMV in its sights, the Oxford University spinout is poised to take its novel VLP vaccine technology into the clinic.
Go or no go? Mirati heads to the FDA
TG Therapeutics and Gilead also await a verdict, and Cytokinetics is set for a panel.